Xcout Intel
Corteria Pharmaceuticals
Corteria Pharmaceuticals is a privately held biopharmaceutical company based in Paris, France, focused on developing first-in-class drugs for indications with high unmet medical need, particularly heart failure.
Subscribe to see Corteria Pharmaceuticals’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Corteria Pharmaceuticals at a glance
Corteria Pharmaceuticals is a biotechnology company headquartered in France. Its most recent funding round, Series A, raised $69.5M in September 2023. Xcout tracks 5 named people at Corteria Pharmaceuticals, including Philip Janiak (CEO).
Corteria Pharmaceuticals leadership
- Philip JaniakCEO
- Stéphane Durant des AulnoisCFO
- Francesca C. LawsonCMO
- Marie-Laure OzouxCSO
- Régis OlivierCAO
Corteria Pharmaceuticals funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series A | $69.5M | 8 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
Corteria Pharmaceuticals competitors
A few of Corteria Pharmaceuticals's closest competitors — see the full list of competitors and alternatives →
Imbria Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company headquartered in Boston, Massachusetts, focused on developing novel cardiovascular therapies.
Acticor Biotech is a clinical-stage biopharmaceutical company headquartered in Paris, France, that specializes in developing innovative treatments for acute thrombotic diseases.
Cardior Pharmaceuticals GmbH is a clinical-stage biopharmaceutical company headquartered in Hannover, Germany. Established in 2016, the company focuses on discovering and developing RNA-based therapeutics for the prevention and treatment of heart diseases.
Nuevocor is a biotechnology research company with its headquarters located in Singapore and additional operations in the United States and France. The company focuses on developing breakthrough gene therapies to treat untreatable cardiomyopathies.
Certa Therapeutics is a private biotechnology company headquartered in Melbourne, Australia, focused on developing innovative precision therapies for the treatment of fibrotic diseases.
Edgewise Therapeutics is a biopharmaceutical company that develops novel therapeutics for individuals facing serious cardiovascular diseases, such as hypertrophic cardiomyopathy and heart failure. The company focuses on muscle science and precision therapies to address unmet medical needs in patients and families.
Get Corteria Pharmaceuticals's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Corteria Pharmaceuticals in Xcout Intel
- 5 named people with titles, LinkedIn and board committees
- 1 funding round with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access